Here are the S-3 shelf registrations from Tarsus Pharmaceuticals, Inc. (TARS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow TARS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARS filings page.
Tarsus Pharmaceuticals, Inc. (TARS) registers up to 2,908,692 shares of common stock for resale by selling stockholders. The shares were issued as consideration for Tarsus’s acquisition of Alkeus Pharmaceuticals, Inc. on September 4, 2026, and Tarsus will receive no proceeds from the resales. The holders may sell from time to time after the registration statement becomes effective, in public or private transactions, at fixed, market-related, varying or negotiated prices. The selling-stockholder table includes, among others, BCLS Fund III Investments, LP with 917,570 shares and Forbion Growth Opportunities Fund III Coöperatief U.A. with 64,087 shares.
Approximately 2,630,416 shares are subject to a two-month lock-up following the acquisition closing, subject to customary exceptions; approximately 1,994,414 shares are subject to volume limitations tied to average trading volume for three months after the lock-up period. Approximately 278,276 shares are subject to neither restriction.
Tarsus Pharmaceuticals, Inc. registered for resale by selling stockholders up to 2,232,144 shares of common stock, comprising 2,098,519 shares of common stock and 133,625 shares issuable upon exercise of pre-funded warrants. The securities were issued in a private placement under an August 5, 2026 purchase agreement. Sales may occur from time to time after effectiveness. Selling stockholders receive resale proceeds; Tarsus receives none from resales but may receive nominal proceeds if holders exercise warrants for cash.
Warrant exercise is prohibited if it would put a holder above its elected 4.99% beneficial-ownership limit. Tarsus, its executive officers and directors, and certain other stockholders agreed, subject to exceptions, not to dispose of or hedge common stock or securities convertible into or exchangeable for common stock from the Purchase Agreement date through the date 90 days after it. Alkeus Pharmaceuticals, Inc.’s audited historical financial statements incorporated by reference include an auditor’s explanatory paragraph about its ability to continue as a going concern. Tarsus had 49,303,413 shares outstanding as of September 25, 2026; its common stock’s last reported sale price was $74.40 on October 12, 2026.